Tsai Karen, Arca Katerina, Ituarte Philip H G, Gernon Thomas, Salehian Behrouz, Bell Diana, Maghami Ellie
Department of Diabetes, Endocrinology and Metabolism City of Hope Comprehensive Cancer Center Duarte California USA.
Division of Head and Neck Surgery, Department of Surgery City of Hope Comprehensive Cancer Center Duarte California USA.
Laryngoscope Investig Otolaryngol. 2024 Dec 20;9(6):e70052. doi: 10.1002/lio2.70052. eCollection 2024 Dec.
Papillary thyroid cancer (PTC) is the most frequent subtype of thyroid cancer with overall favorable survival. Currently, little is known about the PTC experience within the United States (U.S.) Armenians. We performed the first study comparing clinicopathologic variables and clinical outcomes of U.S. Armenian PTC patients to a matched control group of non-Armenians.
We performed a single-center, retrospective, case-control study of adult Armenian PTC patients who received care at COH from 2005 to 2022. Armenian ethnicity was determined by surnames ending in "-ian" and "-yan". We report and compare clinicopathologic presentation and disease outcomes with a gender- and age-matched control non-Armenian population.
Fifty-eight Armenian patients comprised our study cohort. Positive margin status ( = .038), angioinvasion ( = .006), and extrathyroidal extension ( = .014) were more prevalent in the Armenian population. Higher rates of both persistent disease and death due to disease were seen in the Armenians regardless of age groupings. Multivariable analysis revealed significant impact of Armenian status on outcomes. Calculated 5- and 10- year disease-specific survival rates in the Armenian cohort were 88% and 73.2%, respectively, compared with 100% and 94.6% in the non-Armenian group ( < .002). The 5- and 10- year progression-free survival was worse in the Armenian group at 61.8% and 50.1%, respectively, compared with 87.5% and 87.5% in the non-Armenian group ( < .001).
Armenian PTC patients displayed more aggressive disease than non-Armenians. In addition, Armenian PTC patients had higher incidence of disease relapse and worse clinical outcomes.
乳头状甲状腺癌（PTC）是甲状腺癌最常见的亚型，总体生存预后良好。目前，关于美国亚美尼亚人患PTC的情况知之甚少。我们开展了首项研究，比较美国亚美尼亚PTC患者与匹配的非亚美尼亚对照组的临床病理变量和临床结局。
我们对2005年至2022年在COH接受治疗的成年亚美尼亚PTC患者进行了一项单中心、回顾性病例对照研究。亚美尼亚族裔通过姓氏以“-ian”和“-yan”结尾来确定。我们报告并比较了临床病理表现和疾病结局与性别和年龄匹配的非亚美尼亚对照人群。
58名亚美尼亚患者组成了我们的研究队列。切缘阳性状态（P = 0.038）、血管侵犯（P = 0.006）和甲状腺外侵犯（P = 0.014）在亚美尼亚人群中更为普遍。无论年龄分组如何，亚美尼亚人持续性疾病和因病死亡的发生率都更高。多变量分析显示亚美尼亚状态对结局有显著影响。亚美尼亚队列中计算出的5年和10年疾病特异性生存率分别为88%和73.2%，而非亚美尼亚组为100%和94.6%（P < 0.002）。亚美尼亚组的5年和10年无进展生存率分别为61.8%和50.1%，较差，而非亚美尼亚组为87.5%和87.5%（P < 0.001）。
亚美尼亚PTC患者的疾病比非亚美尼亚人更具侵袭性。此外，亚美尼亚PTC患者疾病复发率更高，临床结局更差。
5级。
